Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects

摘要: The invention discloses several novel therapeutic properties and methods of treatment using the recombinant erythropoietin prepared by expression from Apa I restriction fragment human genomic DNA transformed into baby hamster kidney cells (BHK) according to U.S. Patent No. 5,688,697 Powell. This designated herein as Epoetin Omega is shown possesses unexpected superior qualities over other erythropoietins such those Alfa Beta which are or cDNA expressed in Chinese Hamster Ovary (CHO) Nos. 4,703,008 5,955,422 Lin. include, but not limited to, a much higher potency, more rapid response (i.e. no latency), longer effective serum levels, lower antigenicity subjects, activity subjects non-responsive epoetins, fewer adverse side effects incidents thrombosis, reduced nausea, pain at site injection, reduction body pain, most significantly, absence of, risk increased blood pressure hypertension. These provide for including, anemia conditions than fatigue vascular patients adversely effected hypertension with heart oncology settings without chemotherapy radiation therapy, dosing regiments that include doses administration frequencies few once per week less.